摘要
目的评价Bcl-2在三阴性乳腺癌中的预后意义。方法本研究纳入三阴性乳腺癌改良根治术后患者68例,应用Kaplan-Meier生存曲线分析患者总生存(OS)和无病生存率(DFS),并应用Log-rank检验Bcl-2对患者预后价值。结果本组病例中Bcl-2阳性20例,占29.4%。Bcl-2阳性组的中位生存期为(76.0±5.7)个月,而Bcl-2阴性组中位生存期仅为(64.0±5.5)个月(P=0.040)。Bcl-2阳性组中位DFS为(35.0±2.2)个月,而阴性组为(28±2.8)个月(P=0.036)。结论 Bcl-2在三阴性乳腺癌中表达较低,是其预后因素之一。
Objective To evaluate the prognostic significance of Bcl-2 in triple-negative breast cancer patients. Methods All 68 patients with triple-negative breast cancer. Kaplan-Meier survival analyses were carried out for overall survival （OS） and disease free survival （OS）. The log-rank test was used to examine the statistical significance of the differences observed between the groups. Results In this series, 20 （29.4%）patients were with positive Bcl-2 expression. In positive group, the median OS was （76.0±5.7） months, and in the negative group, the median OS was （64.0±5.5）months（P =- 0.040）. The DFS was（35.0±2.2）months and（28±2.8）months, respectively（P = 0.036）. Conclusion Bcl-2 is low expression, and is a prognostic factor for triple-negative breast cancer.
出处
《中国现代医生》
2012年第29期44-46,共3页
China Modern Doctor
